Lauren Stopfer
Executive Director, Proteomics & Innovation Aethon Therapeutics
Seminars
Wednesday 17th September 2025
T Cell Engagers Targeting Drug-Induced Synthetic Neoantigens Address KRAS-G12C Inhibitor Resistance
4:30 pm
- Development of engineered bispecific T cell engagers that recognize KRAS covalent inhibitor–modified peptide-MHC complexes with high affinity and specificity, enabling selective targeting of resistant tumor cells
- Companion immunotherapy approach designed to complement KRASG12C inhibitors by resistant cancer populations, with demonstrated efficacy in vitro and in vivo
- Cross-HLA binding and structural insights supporting broad patient coverage and the molecular basis for recognition of hapten-modified targets
